Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

47.69 +2.32 (+5.11%)
Streaming Delayed Price Updated: 12:45 PM EDT, May 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
MRNA Q1 Deep Dive: International Partnerships and Pipeline Progress Offset Litigation Headwinds
Biotechnology company Moderna (NASDAQ:MRNA) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 260% year on year to $389 mil... 
Via StockStory
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Moderna (MRNA) Q1 2026 Earnings Transcript ↗
Moderna (MRNA) Q1 2026 Earnings Transcript 
Via The Motley Fool
Moderna Inc (NASDAQ:MRNA) Surges Past Q1 Estimates on International Strength ↗
Via Chartmill
News headline image
Moderna (NASDAQ:MRNA) Beats Expectations in Strong Q1 CY2026, Stock Soars
Biotechnology company Moderna (NASDAQ:MRNA) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 260% year on year to $389 mi... 
Via StockStory
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
Via ACCESS Newswire
News headline image
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday morning. Here’s what you need to know. Moderna beat analysts’ revenue expec... 
Via StockStory
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
News headline image
3 Healthcare Stocks With the Most Durable Competitive Moats ↗
These companies offer a clear path to sustained earnings growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
Via ACCESS Newswire
News headline image
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth ↗
It will be a turbulent ride, but patient investors might come out of it much richer. 
Via The Motley Fool
News headline image
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
Via ACCESS Newswire
News headline image
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Via ACCESS Newswire
News headline image
Moderna to Present at Upcoming Conferences in May 2026
Via ACCESS Newswire
News headline image
What's Pushing Moderna Stock Higher Today? ↗
Moderna (NASDAQ:MRNA) shares are moving higher on Monday after the company won FDA Fast Track status for an oncology program. 
Via Benzinga
News headline image
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
Via ACCESS Newswire
News headline image
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
Via ACCESS Newswire
News headline image
3 Unpopular Stocks We Approach with Caution
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
A $2 Trillion IPO and the Space Economy ↗
We discuss the hottest IPO ever, SpaceX, and what the future of the space economy might look like. 
Via The Motley Fool
Topics Economy Initial Public Offering
News headline image
Meet the 2 Formerly Down-and-Out Stocks That Are Outperforming the S&P 500 This Year. Are They Still a Buy? ↗
These stocks have surged in the double-digits. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
News headline image
3 Mid-Cap Stocks We’re Skeptical Of
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco... 
Via StockStory
News headline image
Looks Like M&A Week in 3 Different Sectors ↗
Some large merger & acquisition deals that could shake up the consumer goods and the food distribution industry, plus deals in the healthcare industry. 
Via The Motley Fool
News headline image
You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗
Could this player be heading into a new era of growth? 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
Via ACCESS Newswire
News headline image
2 S&P 500 Stocks with Exciting Potential and 1 We Ignore
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ... 
Via StockStory
Topics Stocks
News headline image
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that... 
Via MarketMinute
Topics Intellectual Property
News headline image
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa... 
Via StockStory
Topics Government Stocks World Trade
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.